Pain ‐ duration exercise WOMAC (VAS or Likert) from 0 to 20 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Pain ‐ resistance exercise WOMAC (VAS or Likert) from 0 to 20 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Function ‐ duration exercise WOMAC from 0 to 68 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Function ‐ resistance exercise WOMAC from 0 to 68 · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Intervention not reported
AOS total (Pain & Physical function) AOS total score. Scale from: 0 to 100 (0 = being no pain/disability, 100 = worst imaginable pain/disability). · patients with osteoarthritis of the ankle
1 finding from 1 review
Intervention not reported
Radiographic Joint Structure Changes · patients with osteoarthritis of the ankle
1 finding from 1 review
Intervention not reported
Quality of Life SF12. Scale from: 0 to 100. · patients with osteoarthritis of the ankle
1 finding from 1 review
Intervention not reported
Number of participants experiencing any serious adverse events · patients with osteoarthritis of the ankle
1 finding from 1 review
Intervention not reported
Number of participants experiencing any adverse event · patients with osteoarthritis of the ankle
The intervention showed no clear difference in number of participants experiencing any adverse event (low certainty).
1 finding from 1 review
Intervention not reported
Participants who withdraw because of an adverse event or any other reason · patients with osteoarthritis of the ankle
1 finding from 1 review
Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
850 participants
High
BASDAI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
193 participants
Moderate
BASFI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
349 participants
High
BASMI Scale from 0 to 10 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiographic progression · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
COX‐2 NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.92 [0.14, 6.21]
669 participants
Moderate
Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in withdrawals due to adverse events Due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.75 [0.46, 1.21]
1165 participants
High
BASDAI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
190 participants
Moderate
BASFI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
356 participants
High
BASMI Scale from 0 to 10 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found